CSIMarket
 
Igc Pharma Inc   (IGC)
Other Ticker:  
 
 
Price: $0.3000 $0.00 1.180%
Day's High: $0.315 Week Perf: 0.00
Day's Low: $ 0.29 30 Day Perf: 6.65 %
Volume (M): 181 52 Wk High: $ 0.49
Volume (M$): $ 54 52 Wk Avg: $0.33
Open: $0.29 52 Wk Low: $0.25



 Market Capitalization (Millions $) 19
 Shares Outstanding (Millions) 64
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 1

Igc Pharma Inc
IGC Pharma Inc is a pharmaceutical company that specializes in researching and developing plant-based therapies. The company is known for its focus on developing and commercializing cannabinoid-based treatments for various medical conditions. It aims to leverage the potential health benefits of cannabinoids to create innovative and effective medications. IGC Pharma Inc also conducts clinical trials and collaborates with academic institutions to further expand its product pipeline. Overall, the company is dedicated to advancing the field of plant-based medicine and improving the lives of patients.


   Company Address: 10224 Falls Road Potomac 20854 MD
   Company Phone Number: 983-0998   Stock Exchange / Ticker: NYSEAMER IGC
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Igc Pharma Inc

IGC Pharma Inc Delivers Impressive Break-Even Milestone, Despite Revenue Dip

The stock market is often seen as a reflection of the overall strength and performance of the economy, and investors are always on the lookout for promising opportunities. In this context, IGC Pharma Inc has recently reached a significant milestone, reaching a break-even point of $0.00 per share for the financial span closing December 31, 2023. This is an admirable achievement when compared to the previous year's break-even rate of $0.00 per share.
During the same reporting season, IGC Pharma Inc experienced a decline in revenue by -38.554% to $0.20 million from $0.33 million in the comparable reporting season a year prior. Sequentially, the revenue fell by -29.897% from $0.29 million. While this drop in revenue may raise concerns, it is important to note that the decline in business is in contrast to the rest of the Major Pharmaceutical Preparations industry, which registered a revenue rise during the same period.
Despite the revenue decline, IGC Pharma Inc realized a net shortfall of $-5.589 million for the financial span closing December 31, 2023. Although this is an increase compared to the net shortfall of $-2.249 million the previous year, it is essential to consider various factors that contribute to this situation rather than solely focusing on the negative aspect.

Igc Pharma Inc

Igc Pharma Inc's Remarkable Financial Performance: An Unconventional Approach in Closing Sep 30, 2023



Igc Pharma Inc, a major player in the pharmaceutical preparations industry, has recently witnessed a decline in its share performance and year-to-date performance. Despite this, the company has managed to surpass market expectations with a notable increase in revenue for the financial period ending September 30, 2023. However, several financial indicators, such as net losses and declining inventories, raise concerns about the company's future prospects and performance.
Declining Share Performance:
Over the past five trading days, Igc Pharma Inc shares have dropped by -2.32%. This decline adds to a year-to-date performance of -12.95%. However, it should be noted that the shares still trade 10.7% above their 52-week low. These fluctuations in share prices reflect the overall uncertainty surrounding the company's financial stability and investor confidence.

Igc Pharma Inc

IGC Pharma Inc Shocks Investors with a Striking 161.792% Revenue Surge in Q1 2024, but Risks Loom Ahead



IGC Pharma Inc's recent earnings report showcased a break-even first quarter of 2024, generating cautious optimism among investors. However, a deeper analysis reveals several underlying concerns that could hinder the company's performance in the near future. Despite a remarkable year-over-year revenue growth and improved net shortfall compared to the same period in the prior year, IGC Pharma Inc's unconventional position within the Major Pharmaceutical Preparations sector raises red flags. Moreover, the decline in inventories and increased accounts receivable demonstrate potential issues that could impact the company's ability to sustain growth. This article delves into the factors that suggest a bearish outlook for IGC Pharma Inc.
Weak Sector Performance:
IGC Pharma Inc's positive earnings stand in stark contrast to the downward trend witnessed across the Major Pharmaceutical Preparations sector. As its peers struggle with declining revenues, IGC Pharma Inc's formidable revenue growth seems like an outlier. This raises concerns about the company's long-term sustainability within a sector grappling with adverse market dynamics.

Igc Pharma Inc

Igc Pharma Inc Struggles to Achieve Profitability Despite Revenue Surge in Q4 2023

Igc Pharma Inc, a pharmaceutical company, recently reported its financial results for the fourth quarter of 2023. Despite a shortfall per stock of $-0.08 per share, the company experienced a significant surge in revenue, which increased by 35.246% to $0.17 million compared to the same period the previous year. This positive revenue growth reflects the company's ability to generate sales and highlights its potential for financial success in the future.
In comparison, during the prior financial reporting period, Igc Pharma Inc's revenue stood at $0.33 million, with earnings per share of $0.00. This suggests a decline in revenue, but the company's recent financial performance demonstrates an apparent recovery.






 

Igc Pharma Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com